Angle PLC
LSE:AGL
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
7.25
31.4
|
| Price Target |
|
We'll email you a reminder when the closing price reaches GBX.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Angle PLC
Angle PLC
Cash Equivalents
Angle PLC
Cash Equivalents Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash Equivalents | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Angle PLC
LSE:AGL
|
Cash Equivalents
£17.9m
|
CAGR 3-Years
24%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Smith & Nephew PLC
LSE:SN
|
Cash Equivalents
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
LivaNova PLC
NASDAQ:LIVN
|
Cash Equivalents
$346.4m
|
CAGR 3-Years
24%
|
CAGR 5-Years
36%
|
CAGR 10-Years
11%
|
|
|
EKF Diagnostics Holdings PLC
LSE:EKF
|
Cash Equivalents
£9.8m
|
CAGR 3-Years
-22%
|
CAGR 5-Years
-5%
|
CAGR 10-Years
-1%
|
|
|
Creo Medical Group PLC
LSE:CREO
|
Cash Equivalents
£9.8m
|
CAGR 3-Years
-32%
|
CAGR 5-Years
-24%
|
CAGR 10-Years
N/A
|
|
|
B
|
Belluscura PLC
LSE:BELL
|
Cash Equivalents
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Angle PLC
Glance View
ANGLE Plc operates as a holding company, through its subsidiaries engages in providing products in cancer diagnostics and foetal health. The company is headquartered in Guildford, Surrey and currently employs 102 full-time employees. The company went IPO on 2004-03-17. The Company’s lead product is the Parsortix cell separation system, which captures very rare cells from the blood. This includes circulating tumor cells (CTCs) in cancer patient blood even when there is less than one CTC in one billion healthy cells. The Parsortix cell separation system uses a microfluidic technology in the form of a one-time use cassette to capture and then harvest circulating tumor cells (CTCs) from blood. The cassette captures CTCs based on their less deformable nature and larger size compared to other blood components. The Company’s translational research includes ovarian cancer, breast cancer, prostate cancer and small cell lung cancer.
See Also
What is Angle PLC's Cash Equivalents?
Cash Equivalents
17.9m
GBP
Based on the financial report for Jun 30, 2024, Angle PLC's Cash Equivalents amounts to 17.9m GBP.
What is Angle PLC's Cash Equivalents growth rate?
Cash Equivalents CAGR 3Y
24%
Over the last year, the Cash Equivalents growth was -19%. The average annual Cash Equivalents growth rates for Angle PLC have been 24% over the past three years .
You don't have any saved screeners yet
